Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalSTU:IC7 80 Buyback Yield % is 0.00 as of Aug. 17, 2026. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 341 Medical Devices & Instruments companies, ICU Medical ranks worse than 293254.84% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for ICU Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:IC7 vs NVST, MMSI, MMED: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, ICU Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where ICU Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (STU:IC7) has a Buyback Yield % of 0.00 as of Aug. 17, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ICU Medical and its competitors. Over the past decade, ICU Medical's Buyback Yield % has ranged from 0.09 to 0.93. According to the industry distribution chart, ICU Medical ranks #999999 out of 341 companies in the Medical Devices & Instruments industry.
Is ICU Medical's Buyback Yield % too high?
ICU Medical's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.93. Based on the distribution chart, ICU Medical ranks #999999 out of 341 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Buyback Yield % compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #999999 out of 341 companies for Buyback Yield %. This places ICU Medical in the lower half of its industry. Historically, ICU Medical's own Buyback Yield % has ranged from 0.09 to 0.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on ICU Medical and its competitors. ICU Medical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Buyback Yield % is 0.00. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Buyback Yield % is 0.00 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (STU:IC7) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for STU:IC7:
Buyback Yield %: 0.00
GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score
Get the complete analysis for STU:IC7
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:IC7 has been successfully added to your 
